Update 2010 of the German AGO recommendations for the diagnosis and treatment of early and metastatic breast cancer-chapter B: Prevention, early detection, lifestyle, premalignant lesions, DCIS, recurrent and metastatic breast cancer

Breast Care

Volumn 5, Issue 5, 2010, Pages 345-351

  Thomssen, Christoph ^a   Harbeck, Nadia ^b  

^a Brustzentrum Halle   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; EVEROLIMUS; FULVESTRANT; GEMCITABINE; LAPATINIB; NAVELBINE; SORAFENIB; SUNITINIB; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; DRUG EFFICACY; DRUG TARGETING; EARLY DIAGNOSIS; HUMAN; INTRADUCTAL CARCINOMA; LIFESTYLE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 78049403981     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000321137     Document Type: Review

References (55)

1. Oxford Levels of Evidence: Oxford Centre for Evidence-based Medicine Levels of Evidence (March 2009; for definitions of terms used see glos-sary at www.cebm.net/?o=1116). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick March 2009.
2. www.ago-online.de ('Leitlinien')
3. Nothacker M, Duda V, Hahn M, Warm M, Degenhardt F, Madjar H, Weinbrenner S, Albert US: Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymp-tomatic women with mammographically dense breast tissue. A systematic review. BMC Cancer 2009;9:335.
4. Houssami N, Hayes DF: Review of preopera-tive magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed early stage breast cancer. CA Cancer J Clin 2009;59:290-302.
5. Bleicher RJ, Ciocca RM, Egleston BL, Sesa L, Evers K, Sigurdson ER, Morrow M: Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg 2009;209:180-187.
6. Brennan ME, Houssami N, Lord S, Macaskill P, Irwig L, Dixon M, Warren, R, Ciatto S: Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast can-cer: systematic review and meta-analysis of incre-mental cancer detection and impact on surgical management. JCO 2009;27:5640-5649.
7. Kellen E, Vansant G, Christiaens M-R, Neven P, van Limbergen E: Lifestyle changes and breast cancer prognosis: a review Breast Cancer Res Treat 2009;114:13-22.
8. Li CI, Daling JR, Porter PL, Tang MT, Malone KE: Relationship between potentially modifiable lifestyle factors and risk of second primary contra-lateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol 2009;27:5312-5318.
9. WHO: Pathology and genetics of tumours of the breast and female genital organs; in Tavassoli F, Devilee P (eds): World Health Organization. Classification of Tumours. Lyon, IACR Press, 2003, pp. 9-112.
10. Kreipe, H, Höfler H, Lebeau A, Pickartz H, Schmidt D: Ergebnisse der Referenzpathologie im Mammographie-Screening. Pathologe 2008; 29(suppl):178-180.
11. Ellis IO, Coleman D, Wells C, Kodikara S, Paish EM, Moss S, Al-Sam S, Anderson N, Bobrow L, Buley I, Connolly CE, Dallimore NS, Hales S, Hanby A, Humphreys S, Knox F, Lowe J, Macartney J, Nash R, Parham D, Patnick J, Pinder SE, Quinn CM, Robertson AJ, Shrimankar J, Walker RA, Winder R: Impact of a national external quality as-sessment scheme for breast pathology in the UK J Clin Pathol 2006;59:138-145.
12. Albert US (ed): Stufe-3-Leitlinie Brustkrebs-Früh-erkennung in Deutschland. 1. Aktualisierung 2008. Muenchen, Zuckschwerdt Verlag, 2008.
13. Kreienberg R, Kopp I, Albert US, Bartsch H, Beckmann M, Berg D, Bick U, du Bois A, Budach W, Dunst J, et al.: Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. München, Zuckschwerdt Ver-lag, 2008.
14. Noguchi S, Motomura K, Inaji H, Imaoka S, Koya-ma H: Clonal analysis of predominantly intraductal carcinoma and precancerous lesions of the breast by means of polymerase chain reaction. Cancer Res 1994;54:1849-1853. (Pubitemid 24116198)
15. Ciatto S, Houssami N, Ambrogetti D, Bianchi S, Bonari R, Brancato B, Catarzi S, Risso G: Accu-racy and underestimation of malignancy of breast core needle biopsy: the Florence experience of over 4,000 consecutive biopsies. Breast Cancer Res Treat 2007;101:291-307.
16. Brem RF, Behrndt VS, Sanow L, Gatewood OM: Atypical ductal hyperplasia: histologic underesti-mation of carcinoma in tissue harvested from im-palpable breast lesions using 11-gauge stereotacti-cally guided directional vacuum-assisted biopsy. AJR 1999;172:1405-1407.
17. Bedei L, Falcini F, Sanna P: Atypical ductal hyper-plasia of the breast: the controversial management of a borderline lesion. Experience of 47 cases di-agnosed at vaccumassisted biopsy. Breast 2006; 15:196-202.
18. Zagrafos G, Zagouri F, Sergentanis T, Nonni A, Koulocheri D, Folou M, Panopoulou E, Paranas N, Foliadis C, Bramis J: Minimizing underestima-tion rate of microcalcifications excised via vacuum-assisted breast biopsy: ablind study. Breast Cancer Res Treat 2008;109:397-402.
19. Liberman L, Holland A, Marjan D, Murray M, Bertelle L, Morris E, Dershew D, Wynn R: Under-estimation of atypical ductal hyperplasia at MRI-guided 9-gauge vacuum-assisted breast biopsy. AJR 2007;188:684-690.
20. Weir R, Day P, Ali W: Risk factors for breast can-cer in women: a systematic review of the literature. Christchurch, New Zealand Health Technology Assessment (NZHTA), 2007.
21. Degnim A, Visscher W, Berman H, Frost M, Sellrs T, Vierkant R, Maloney S, Pankratz V, de Groen P, Lingle W, et al.: Stratification of breast cancer risk in women with atypia: a Mayo Cohort Study. JCO 2007;25:2671-2677.
22. Dillon MF, McDermott EW, Hill AD, O'Doherty A, O'Higgins N, Quinn CM: Predictive value of breast lesions of 'uncertain malignant potential' and 'suspicious for malignancy' determined by needle core biopsy. Ann Surg Oncol 2007;14:704-711.
23. Pandey S, Kornstein MJ, Shank W, de Paredes ES: Columnar cell lesions of the breast: mammographic findings with histopathologic correlation. Radio-graphics 2007;27:S79-S89.
24. Collins L, Achacoso N, Nekhlyudov L, Fletcher S, Haque R, Quesenberry C, Alshak N, Puligandla B, Brodsky G, Schnitt S, et al.: Clinical and pathologi-cal features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analy-sis of 543 patients. Mod Pathol 2007;20:1149-1155.
25. Boulos F, Dupont W, Simpson J, Schuyler P, Sanders M, Freudenthal M, Page D: Histologic associations and long-term cancer risk in columnar cell lesions of the breast. Cancer 2008;113:2415-2421.
26. Kunju L, Kleer C: Significance of flat epithelial atypia on mammotome core needle biopsy: should it be excised? Hum Pathol 2006;38:35-41.
27. David N, Labbe-Devilliers C, Moreau D, Lous-souarn D, Campion L: Diagnosis of flat epithelial atypia (FEA) after stereotactic vacuum-assisted biopsy (VAB) of the breast: what is the best management-systematic surgery for all or follow-up? J Radiol 2006;87:1671-1677.
28. Pinder S, Provenzano E, Reis-Filho J: Lobular in situ neoplasia and columnar cell lesions: diag-nosis in breast core biopsies and implications for management. Pathology 2007;39:208-216.
29. Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, Aref A: Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: anal-ysis of surveillance, epidemiology, and end results data. J Clin Oncol 2005;23:5534-5541.
30. Cangiarella J, Guth A, Axelrod D, Darvishian F, Singh B, Simsir A, Roses D, Mercado C: Is surgical excision necessary for the management of atypical lobular hyperplasia and lobular carcinoma in situ diagnosed on core biopsy? Arch Pathol Lab Med 2008;132:979-983.
31. Brem R, Lechner M, Jackman R, Rapeleya J, Evans W, Philpotts L, Hargreaves J, Wasden S: Lobular neoplasia at percutaneous breast biopsy: variables associated with carcinoma at surgical ex-cision. AJR 2008;190:637-641.
32. Arpino G, Allred D, Mohsin S, Weiss H, Conrow D, Elledge R: Lobular neoplasia on core-needle biopsy: clinical significance. Cancer 2004;101:242-250.
33. Elsheikh T, Silverman J: Follow-up surgical exci-sion is indicated when beast core needle biopsies show atypical lobular hyperplasia or lobular car-cinoma in situ: a correlative study of 33 patients with review of the literature. Am J Surg Pathol 2005;29:534-543.
34. Lakhani I, Audretsch W, Cleton-Jensen A, Cutuli B, Ellis I, Eusebi V, Greco M, Houslton R, Kuhl C, Kurtz J, et al.: The management of lobular carcino-ma in situ (LCIS). Is LCIS the same as ductal carci-noma in situ (DCIS)? Eur J Cancer 2006; 42: 2205-2211.
35. Kopans DB: LCIS found at core needle biopsy may not need surgical excision. AJR 2008;191:W152.
36. Chandandeep S, O'Donnell J, Tismenetsky M, Bleiweiss I, Jaffer S: Lobular neoplasia on core needle biopsy does not require excision. Cancer 2008;112:2152-2158.
37. Ciocca R, Li T, Freedman G, Morrow M: Presence of lobular carcinoma in situ does not increase re-currence in patients treated with breast-conserving therapy. Ann Surg Oncol 2008;15:2263-2271.
38. Silverstein MJ, Craig PH, et al.: Developing a prognostic index for ductal carcinoma in situ of the breast. Are we there yet? Cancer 1196;78:1138-1140.
39. Lagios MD, Page DL, et al.: Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 2006;24:3809-3811; author reply 3811-3802.
40. Goodwin A, Parker S, et al.: Post-operative radio-therapy for ductal carcinoma in situ of the breast-a systematic review of the randomised trials. Breast 2009;18:143-149.
41. Dunne C, Burke JP, et al.: Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 2009;27:1615-1620.
42. Jones HA, Antonini N, et al.: Impact of patho-logical characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol 2009;27:4939-4947.
43. National Institute Of Health, State-Of-The-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ (DCIS), September 22-24, 2009 consensus.nih.gov/2009/DCIS%20images/dcis-draftstmt.pdf.
44. Alpert TE, Kuerer HM, Arthur DW, Lannin DR, Haffty BG: Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserv-ing surgery and prognostic factors for salvage breast preservation. Int J Radiat Oncol Biol Phys 2005;63:845-851.
45. Thompson AFtBRITSB, Dundee, United King-dom: A prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the breast recurrence in tissues study (BRITS). Cancer Res 2009;69:abstr 4053.
46. Gibson L, Lawrence D, Dawson C, Bliss J: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009:(4)CD003370.
47. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605-1613.
48. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior en docrine treatment. J Clin Oncol 2002;20:3396-3403.
49. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko I, Khasanov R, Verhoeven D, Pedrini J, Lichinitser M, Pendergrass K, Garnett S, Lindemann JPO, Sapunar F, Martin M; Investiga-tors oBotC: CONFIRM: A phase III, randomized, parallel-group trial comparing fulvestrant 250 mg vs. fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. Cancer Res 2009;69:abstr 25.
50. Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, Lindemann J, Ellis MJ: Activity of fulvestrant 500 mg versus anas-trozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009;27:4530-4535.
51. Bergh J, Jönsson PE, Lidbrink E, Trudeau M, Eiermann W, Brattström D, Lindemann J, Wiklund F, Henriksson R: First results from FACT-an open-label, randomized phase III study inves-tigating loading dose of fulvestrant combined with anastrozole versus anastrozole at first relapse in hormone receptor positive breast cancer. Cancer Res 2009;69:abstr 23.
52. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M: Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroi-dal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664-1670.
53. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M: Lapatinib combined with letrozole versus letro-zole and placebo as first-line therapy for postmeno-pausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-5546.
54. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Revil C, Jones A: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hor-mone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-5537.
55. Huober J, Fasching P, Paepke S, Kubista E, Barsoum M, Wallwiener D, Harbeck N: Letro-zole in combination with trastuzumab is superior to letrozole monotherapy as first line treatment in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer (MBC)-results of the eLEcTRA trial. Cancer Res 2009;69:abstr 4094.